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found a survival advantage from SIRT compared to standard care in chemother-
apy-refractory patients. This study was used in combination with other sources to 
model the cost-effectiveness of SIRT vs best supportive care (BSC) in this indica-
tion. Methods: A state-transition model was developed, with three health states, 
based on survival outcomes from a retrospective cohort study in chemotherapy-
refractory mCRC comparing yttrium-90 resin microspheres (SIR-Spheres; Sirtex, 
Sydney, Australia) vs. BSC. The model was developed from the perspective of the 
National Health Service in Italy. The model included costs for treatment acquisition, 
pre-treatment work-up and delivery of microspheres, and chemotherapy received in 
addition to, instead of, or after, SIRT. In addition costs of managing AEs and a cost of 
death were included. Costs were obtained from the University Hospital in Bologna, 
Agenzia Italiana del Farmaco, and the literature. Utility data was not available from 
the study, so was taken from a recent NICE economic evaluation in the same indica-
tion. Results: SIRT increased survival resulting in a life-year gain of 1.35 (2.12 vs 
0.98) life years and a quality-adjusted life year (QALY) gain of 0.83 (1.52 vs 0.70). The 
costs of SIRT, monitoring and further treatment were greater in the SIRT arm with 
partial cost-offset through a reduction in adverse events. Overall, SIRT lead to an 
increase in costs of € 24,626 (€ 39,973 vs € 15,347), resulting in a cost/QALY of € 29,850. 
Probabilistic sensitivity analysis showed a 97% chance of SIRT being cost-effective 
at a threshold of € 50,000/QALY. ConClusions: The analysis demonstrates that 
SIRT using resin yttrium-90 microspheres has the potential of being a cost-effective 
option in the treatment of patients with chemotherapy-refractory liver metastases 
resulting from colorectal cancer.
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objeCtives: To determine the cost-effectiveness of bendamustine versus fludara-
bine for the first line treatment of CLL in Mexico. Methods: An economic model 
was constructed from the Mexican public payer perspective, with a 25-year (life-
time) horizon and a discount rate of 5%. The model included three health states, 
progression-free (PF), progressive disease (PD), and death. Clinical inputs (Kaplan-
Meier curves, response rates, hazard ratios (HRs) and adverse event (AE) rates 
were from a phase 3 trial comparing bendamustine and chlorambucil, and from 
a network meta-analysis. Resource use data were from interviews with Mexican 
hematologists treating CLL. Resource use for PF patients was weighted based 
on treatment response. Unit costs were obtained from Mexican Social Security 
Institute (IMSS) and were expressed in 2013 Mexican Pesos. Univariate and proba-
bilistic sensitivity analyses were conducted to determine the key drivers of cost-
effectiveness, and the uncertainty around the results, respectively. Results: 
Total lifetime costs for bendamustine and fludarabine were $660,796 and $536,068, 
respectively. Bendamustine patients accrued more LYs (6.83 vs. 5.98), QALYs (5.13 
vs. 4.25), and PF LYs (2.97 vs. 1.13) compared to fludarabine patients. The ICERs 
were $146,848 (cost per LY), $142,853 (cost per QALY) and $67,647 (cost per PF LY). 
Univariate sensitivity analysis revealed the cost per LY ICER was most sensitive 
to number of bendamustine cycles, the PFS for bendamustine vs. chlorambucil 
and the cost of bendamustine. Probabilistic sensitivity analysis with 1,000 itera-
tions predicted bendamustine had a 48% chance of being cost-effective, compared 
to fludarabine, at a willingness to pay (WTP) of $125,000. ConClusions: At a 
WTP of $125,000 (GDP per capita of Mexico) bendamustine is cost effective versus 
fludarabine.
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objeCtives: To estimate the cost-effectiveness of bortezomib, thalidomide, and 
dexamethasone (VTD) induction therapy, versus TD alone in newly diagnosed 
multiple myeloma (ndMM) patients eligible for autologous stem cell transplanta-
tion (ASCT) in Germany. Methods: A life-time Markov model with monthly cycles 
is used to model disease progression and generate cost per quality-adjusted life 
years (QALY). It includes five health states; four of which are related to the lines 
of treatment, and death. Patients enter the first line state at randomisation and 
receive induction usually followed by ASCT. Patients can move to the next line 
upon progression or die within a line, until they enter the final (4+) line where 
they remain until death. Transition probabilities are derived from multi-state 
survival analysis of patient level data from the PETHEMA-trial for first line, the 
APEX-trial for second and third line, and an observational data set (eVOBS) for 
further lines. The model uses ASCT and time dependent utilities from the litera-
ture and trial estimated grade ≥ 3 adverse events (AEs) associated disutilities to 
calculate the QALYs. Cost estimates related to treatments, transplant and AEs 
are based on German specific sources. A payer’s perspective is chosen. Discount 
rates of 3% for both cost and utilities are applied. Results: Total life years of 
6.38 VTD and 5.06 for TD with first line duration of 50.47 versus 32.85 months 
respectively. Incremental costs of VTD versus TD are 22,179€ [95%CI:6,950€ ;33,528€ ] 
and incremental QALYs are 0.72 [95%CI:0.33;1.20], resulting in an ICER of € 30,655 
per QALY gained. The univariate analyses show that the model is most sensitive 
nant strategy over WLC alone when used at initial TURB for patients diagnosed with 
NMIBC in England and Wales, with improved patient outcomes and cost-savings 
expected to offset investment in HAL.
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objeCtives: Currently, there are several tyrosine kinase inhibitors (TKI) approved 
for the treatment of chronic myeloid leukemia (CML). The aim of our study was 
to evaluate the long-term cost-effectiveness of different therapy regimens for 
CML focusing on the evaluation of the uncertainty using probabilistic sensitiv-
ity analysis (PSA). Methods: We performed a cost-effectiveness analysis using 
a state-transition Markov model. The model evaluates seven treatment strate-
gies including different combinations of TKIs as well as chemotherapy or stem 
cell transplantation. For model parameters, we used published trial data, and 
Austrian clinical, epidemiological, and economic data from the Austrian CML 
registry, statistical and economic databases. We performed a cohort simulation 
over a lifelong time horizon, adopted a societal perspective with an annual 3% dis-
count rate. We conducted extensive uncertainty analyses and contrasted different 
methodological approaches to define parameter uncertainty distributions from 
our source data. We compared the base-line derived from the mean parameter 
values with the mean outcomes of all PSA scenarios. Results: In the base-case 
efficiency frontier, nilotinib without second-line TKI resulted in an ICUR (1) of 
118,600 € /QALY compared to the baseline strategy imatinib without second-line 
TKI. Imatinib followed by nilotinib after failure yielded an ICUR (2) of 123,900 € /
QALY compared to nilotinib without second-line TKI. Nilotinib followed by dasat-
inib after failure resulted in an ICUR (3) of 149,400 € /QALY compared to imatinib 
followed by nilotinib after failure. The remaining strategies were excluded due to 
absolute or extended dominance. The PSA resulted in ICURs of (1) 116,200 € /QALY 
(2) 130,300 € /QALY and (3) 130,300 € /QALY. ConClusions: Based on our analysis, 
we recommend imatinib followed by nilotinib as the most cost-effective treatment 
strategy including a second-line TKI. Mean results from PSA show only small 
deviation from the base-case analysis. When new path to cure data are available, 
results will need to be updated.
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objeCtives: To review published cost-effectiveness studies which evaluate radio-
therapy in individuals with breast, cervical, colorectal, head and neck, or prostate 
cancer. To compare the economic methods used with the guidelines used in the 
appraisal programme for the National Institute of Health and Care Excellence (NICE) 
in the UK. Methods: Systematic searches of seven databases (Medline, EMBASE, 
CDSR, NHSEED, HTA, DARE and EconLit) were conducted in July 2012. In addition, 
research registers, the NICE website and conference proceedings were searched. 
Studies that reported results of economic evaluations of radiotherapy interven-
tions in terms of incremental quality adjusted life-years or life-years for individuals 
diagnosed with cancers were included. The quality of these studies was assessed 
in terms of meeting, essential, preferred and UK NICE-specific requirements for 
economic evaluations. Results: Twenty-nine studies satisfied the inclusion criteria 
(breast= 14, colorectal= 2, prostate= 10, cervical= 0, head and neck= 3). The majority 
(13) of the studies were set in the US with just 2 conducted in the UK. Considering 
essential methodological criteria, only 3 (10%) studies used estimates for clinical 
effectiveness which were identified by systematic literature review. Just a quarter 
(8/29) used health related quality of life data from patients with the particular can-
cers. While the majority of studies used one-way sensitivity analyses, only a third 
(10/29) reported the results of a full probabilistic sensitivity analysis. Additional 
essential criteria such as the use of an appropriate horizon, a clear description of 
both the comparators and the patient group indication were generally satisfied. 
However, as only 2 of the studies were conducted in the UK, the majority of the UK 
NICE specific requirements were not met. ConClusions: This review indicates 
there is little robust evidence of the cost-effectiveness of radiotherapy interventions 
in these cancers and very little evidence which could be used to support decision 
making in the UK.
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objeCtives: SIRT using resin microspheres of yttrium-90 can be used to treat liver 
metastases resulting from colorectal cancer (CRC). A retrospective cohort study 
